相关实验视频

Updated: Jun 23, 2025

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

冠状动脉斑块侵蚀:流行病学,诊断和治疗

Panagiotis Theofilis¹, Panayotis K Vlachakis¹, Aggelos Papanikolaou¹

¹1st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

International journal of molecular sciences

|June 19, 2024

概括

斑块侵蚀 (PE) 占急性冠状动脉综合征 (ACS) 的近40%,影响年轻女性并表现出季节性模式. 了解PE PE的理解

科学领域:

心脏病学心脏病学
生物医学科学生物医学科学

背景情况:

斑块侵蚀 (PE) 是急性冠状动脉综合征 (ACS) 的未被认可的原因,与斑块破裂 (PR) 不同.
最近的数据表明,在ACS患者中,PE患病率约为40%,这挑战了基于尸检的旧估计.
长期发育不成比例地影响年轻人,特别是女性,并且经常与非ST段升高心肌梗塞有关.

研究的目的:

阐明流行病学,分子机制,诊断进展和治疗策略,用于急性冠状动脉综合征中的斑块侵蚀.
为了突出PE与斑块破裂相比的独特特征.
探索PE管理的未来方向.

主要方法:

关于PE流行率和人口统计的最新流行病学研究的综述.
分析涉及PE病理生理学的分子途径,包括炎症和内皮切割应激.
评估目前和新兴的血管内成像技术 (OCT,NIRS,IVUS) 和PE诊断中的AI.
评估不断发展的治疗方法,包括抗血栓治疗和药物涂层气球.

主要成果:

乳腺前列腺发病率显著 (在ACS中约40%),具有明显的人口统计 (年轻人,女性) 和季节性变化.
PE涉及的炎症比PR少,对内皮切割应激,中性粒细胞激活和氨酸酶2的潜在作用.
先进的血管内成像和人工智能增强PE诊断和特征.
较少的侵入性治疗,如无支架的抗血栓药物,对PE管理有希望.

结论:

斑块侵蚀是急性冠状动脉综合征的主要,明显的贡献者,具有独特的流行病学和分子形状.
血管内成像和人工智能正在改变PE诊断.
针对PE的个性化治疗策略正在发展,朝着不那么侵入性的选择迈进.

关键词:

急性冠状动脉综合征急性冠状动脉综合征动脉样硬化动脉样硬化冠状动脉疾病是一种冠状动脉疾病.分子机制的分子机制.光学连贯性断层扫描 (optical coherence tomography) 是一种光学连贯性断层扫描技术.斑块侵蚀侵蚀斑块侵蚀

更多相关视频

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

相关概念视频

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Barrett Esophagus-II: Clinical Manifestations and Management

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...